Stockscreener 앱 받기
1.93
3.02%
-0.06
시간 외 거래:
1.84
-0.09
-4.66%
Hcw Biologics Inc 주식(HCWB)의 최신 뉴스
HCW Biologics prices $1.5M private placement offering By Investing.com - Investing.com Australia
HCW Biologics Announces Strategic $1.5 Million Financing - TipRanks
HCW Biologics Raises $1.5 Million in Private Placement of Pre-Funded Warrants; Common Warrants Pending Vote - TradingView
HCW Biologics Prices $1.5 Million Private Placement With Existing Stockholder - Quiver Quantitative
HCW Biologics Announces Pricing of $1.5 Million Private Placement - GlobeNewswire
HCW Biologics Board Withdraws Performance Equity Plan Proposal After Stockholder Feedback - Minichart
HCW Biologics Updates Special Meeting Proxy Materials - TipRanks
HCW Biologics removes equity-plan proposal, reschedules special meeting - TradingView
HCW Biologics (HCWB) asks holders to lift warrant share cap - Stock Titan
HCW Biologics regains Nasdaq bid price compliance - scanx.trade
HCWB Looks 92.8% Undervalued on GF Value™ Despite Financial Dist - GuruFocus
HCW Biologics signs global HCW11-006 distribution deal - TipRanks
HCW Biologics Signs Akron Biotech Distribution Deal for CAR-T Manufacturing Reagent - Yahoo Finance
HCW Biologics signs distribution deal with Akron Biotech By Investing.com - Investing.com Canada
HCWB Stock In Focus As Holders File To Sell 1.24M Shares - timothysykes.com
HCWB Stock Faces Pressure As Shareholders Plan Secondary Sale - StocksToTrade
HCW Biologics signs distribution deal with Akron Biotech - Investing.com
HCW Biologics Enters Exclusive Distribution Agreement with Akron Biotech for HCW11-006 Reagent Commercialization - Quiver Quantitative
A reagent may help make longer-lasting immune cells. HCW Biologics will supply it to Akron. - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Hcw Biologics Stock Price Forecast. Should You Buy HCWB? - StockInvest.us
HCW Biologics (NASDAQ: HCWB) asks investors to vote on more equity than its current share count - Stock Titan
HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment - Investing News Network
HCWB Looks 90.0% Undervalued on GF Value™ - GuruFocus
HCW Biologics Strengthens U.S. Patent Estate for Its Lead - GlobeNewswire
HCW Biologics Inc. SEC Filing (Sep 1, 2026) - Stock Titan
HCW Biologics (HCWB) Rises 8.2% to $3.43 as Momentum Builds Toward Key ResistanceBackspread Trade - siam.in
HCW Biologics Inc (HCWB) Valuation: PE, PB & Fair Value Analysis - TradingKey
HCWB Q1 2026 Earnings: EPS Surges to $2.22, Delivering a 182% Surprise Above ExpectationsSpecial Dividend Alert - dars.gov.et
HCW Biologics advances cancer therapies with TGF-β/IL-15 fusion - Investing.com Canada
Human studies showed HCW Biologics’ fusion expanded progenitor T cells and natural killer cells - Stock Titan
HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel - GlobeNewswire
HCW (HCWB) Financial Update: The EPS Result Is Above Expectation in the Latest Reading; Investor Response: The Share Price Adds 2.83% on the DayEarnings Call Transcript - vinanet.vn
HCW (HCWB): Finishes 2.83% Up at $2.18 in the Latest Reading; Range Check: Price Remains Between $2.07 Support and $2.29 ResistanceBPI Bull Confirmed - vinanet.vn
HCW Biologics (NASDAQ: HCWB) registers PIPE, warrant shares - Stock Titan
581,047 Common Stock of HCW Biologics Inc. are subject to a Lock-Up Agreement Ending on 20-AUG-2026. - marketscreener.com
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
HCWB Q1 2026 Earnings: EPS of $2.22 Smashes Consensus by 182.44% Despite No RevenueHigh Estimate Range - vinanet.vn
HCW Biologics (HCWB) Slides 8.4% to $2.68 as Key Support Level Comes into FocusDividend Arbitrage - vinanet.vn
HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results - The Manila Times
HCW Biologics requests FDA meeting for HCW11-018b solid tumor candidate - scanx.trade
HCW Biologics Q2 net loss widens to $5.2M despite revenue surge - scanx.trade
Form 8K HCW Biologics Inc For: 14 August By Investing.com - Investing.com Nigeria
HCW Biologics Inc. Q2 2026: Revenue $135.6K, EPS $(11.58) — 10-Q Summary - TradingView
HCW Biologics (HCWB) posts higher 2026 revenue but flags going-concern risk - Stock Titan
HCW Biologics Reports Second Quarter 2026 Financial Results and Updates HCW9302 Alopecia Areata Program, HCW11-018b Development and Financing Activities - Quiver Quantitative
HCW Biologics trial: 3 alopecia patients cut SALT scores 25%+ - Stock Titan
HCWB Q1 2026 Earnings: Surprise EPS of $2.22 vs. Expected Loss, Yet Shares Slip 3.06%Core Business Growth - dars.gov.et
HCW Biologics Inc (HCWB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
HCWB Q1 2026 Earnings: EPS of $2.22 Surges Past Loss EstimatesQuarterly Financial Update - dars.gov.et
HCW Biologics (HCWB) completes $1.6M exempt equity and warrant sale - Stock Titan
HCW Biologics | D: Filing D - Moomoo
HCWB Q2'26 Earnings: EPS estimate is (1.98) USD - TradingView
Price to earnings forward of HCW Biologics Inc. – NASDAQ:HCWB - TradingView
HCW Biologics (HCWB) director buys stock, entitled to new warrants - Stock Titan
3.06%
2.55%
자본화:
|
볼륨(24시간):